RVV Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

posted Nov 01, 2024 9:00am  by  Revive Therapeutics Ltd
The DRDC conducted an additional control study to achieve optimal dosing. The research study is progressing and is now expected to be completed with final results by the end of calendar 2024. The results from this research study, if promising, will determine further studies to facilitate FDA and Health Canada approvals for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning and explore its potential for traumatic brain injury caused by concussive or explosive forces and viral infections. ...read more